Tables
- TABLE 1
Recent and ongoing clinical trials of new and emerging therapies for NTM
Agent Company Mechanism of action Target population Phase ClinicalTrials.gov identifier Status ALIS Insmed Inc. Inhaled amikacin Treatment refractory MAC III NCT02344004 Completed ALIS Insmed Inc. Inhaled amikacin Treatment naïve MAC III NCT04677569 Recruiting ALIS Insmed Inc. Inhaled amikacin Treatment refractory M. abscessus II NCT03038178 Completed Bedaquiline Janssen Pharmaceutical K.K. Inhibition of energy metabolism Treatment refractory MAC II/III NCT04630145 Recruiting Clofazimine Inhibition of DNA replication MAC II NCT02968212 Recruiting Omadacycline Paratek Pharmaceuticals Inc. Inhibition of protein synthesis (tetracycline) M. abscessus II NCT04922554 Recruiting Linezolid Siam Pharmaceutical Ltd. Inhibition of protein synthesis NTM pulmonary disease IV NCT03220074 Recruiting Inhaled nitric oxide Mycobacterial killing NTM pulmonary disease NCT03748992 Completed Inhaled nitric oxide Mallinckrodt Pharmaceuticals Mycobacterial killing NTM pulmonary disease NCT03473314 Completed Inhaled nitric oxide Mallinckrodt Pharmaceuticals Mycobacterial killing NTM pulmonary disease NCT03331445 Terminated Inhaled nitric oxide Beyond Air Inc. Mycobacterial killing M. abscessus II NCT03208764 Completed Inhaled nitric oxide Beyond Air Inc. Mycobacterial killing Treatment refractory NTM NCT04685720 Recruiting IFN-γ/GM-CSF Immunomodulation MAC pulmonary disease I NCT00111397 Completed GM-CSF Savara Inc. Immunomodulation Treatment refractory NTM II NCT03421743 Completed GM-CSF Savara Inc. Immunomodulation Cystic fibrosis NTM infection II NCT03597347 Terminated IL-7 Revimmune Immunomodulation Treatment refractory NTM II NCT04154826 Recruiting i.v. Gallium Disruption of iron metabolism Cystic fibrosis NTM infection Ib NCT04294043 Recruiting ALIS: amikacin liposome inhalation suspension; MAC: Mycobacterium avium complex; IFN-γ: interferon gamma; GM-CSF: granulocyte–macrophage colony-stimulating factor; IL: interleukin.